Avalo Therapeutics (AVTX) Stock Price, Quote, News & History | Benzinga

SPY777.29−0.16%QQQ743.86−0.99%BTC/USD82,308.68+0.70%DIA518.08+0.38%GLD382.24−0.61%TLT77.97−0.01%

Avalo Therapeutics Inc (AVTX) Stock Price, Quote, News & History

AVTXNASDAQ

Trade with Public

Trade with Public

$13.24

-0.41-3%

Last update: Oct 12, 4:27 PM

$13.24

-0.41-3%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$13.56

Close

$13.24

Volume / Avg.

500.70K / 922.95K

Day Range

$13.24 - $13.24

52 Wk Range

12.51 - 24.27

Market Cap

$732.05M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

27

Short Interest

21.3%

Days to Cover

8.8

Recent Avalo Therapeutics, Inc. News

This ICU Medical Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed outlook on top names. Find all rating changes on Benzinga's analyst ratings page. See analyst views on ICUI, BDSX,.

Avi Kapoor

This FormFactor Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday

Wall Street analysts upgraded EDU, MKTX, and FORM stocks. Check out their ratings on Benzinga's analyst ratings page before buying EDU.

Avi Kapoor

This Sailpoint Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday

Wall Street analysts downgrade ADBE and SAIL, cutting price targets. Check other analysts' views on these stocks. Photo via Shutterstock.

Avi Kapoor

This Keurig Dr Pepper Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Top Wall Street analysts changed their outlook on top names. See analyst rating changes for PepsiCo, Octave Intelligence, Fervo Energy, Avalo Therapeutics, and Keurig Dr Pepper.

Avi Kapoor

These Analysts Revise Their Forecasts On Avalo Therapeutics After Q1 Results

Avalo Therapeutics reported better-than-expected Q1 loss due to positive trial results. Analysts maintain Buy ratings with lowered price targets.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-68.29M

Investing Cash Flow (TTM)

-315.28M

Financing Cash Flow (TTM)

426.66M

Free Cash Flow (TTM)

-68.29M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

43.09M

Analyst Trends and Forecast

6

May

2

Jun

1

Jul

2

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$332.02M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

5559.00

PB Ratio (TTM)

1.63

Earnings Yield % (TTM)

-32.31%

Earnings Yield % (FWD)

-18.17%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$8.37

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$85.38M

Debt to Equity

0.00

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-